0924 GMT - Roche maintaining its 2025 targets, despite the current uncertain political environment from the U.S., reassures investors, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's key growth drivers continue to grow well, whereas new blockbuster eye drug Vabysmo missed consensus' expectations, he says. Shares are flat at 257.90 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 05:24 ET (09:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.